Charles River Laboratories Intl. (NYSE:CRL) had its price target boosted by Argus from $190.00 to $235.00 in a research note released on Monday morning, The Fly reports. Argus currently has a buy rating on the medical research company’s stock.

A number of other equities analysts also recently issued reports on CRL. Zacks Investment Research downgraded shares of Charles River Laboratories Intl. from a buy rating to a hold rating in a report on Thursday, July 16th. Bank of America raised Charles River Laboratories Intl. from a neutral rating to a buy rating and set a $192.00 target price for the company in a research note on Wednesday, July 1st. Citigroup upped their target price on Charles River Laboratories Intl. from $190.00 to $255.00 and gave the stock a buy rating in a research note on Thursday, August 6th. Jefferies Financial Group raised Charles River Laboratories Intl. from a hold rating to a buy rating and increased their price objective for the company from $213.00 to $254.00 in a research note on Thursday, September 10th. Finally, Morgan Stanley upped their target price on Charles River Laboratories Intl. from $175.00 to $245.00 and gave the company an overweight rating in a report on Thursday, August 6th. Three research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $199.74.

NYSE:CRL opened at $221.98 on Monday. Charles River Laboratories Intl. has a 12 month low of $95.58 and a 12 month high of $228.86. The firm has a market cap of $11.03 billion, a PE ratio of 40.88, a price-to-earnings-growth ratio of 2.18 and a beta of 1.19. The company has a quick ratio of 1.46, a current ratio of 1.70 and a debt-to-equity ratio of 1.26. The company’s 50-day moving average price is $213.08 and its two-hundred day moving average price is $172.35.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $1.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.31. Charles River Laboratories Intl. had a net margin of 9.87% and a return on equity of 21.58%. The firm had revenue of $682.60 million for the quarter, compared to analyst estimates of $638.70 million. During the same period in the prior year, the firm posted $1.63 earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, research analysts expect that Charles River Laboratories Intl. will post 7.22 EPS for the current fiscal year.

In other Charles River Laboratories Intl. news, Director George Massaro sold 1,943 shares of the stock in a transaction on Monday, September 14th. The shares were sold at an average price of $219.91, for a total value of $427,285.13. Following the completion of the sale, the director now owns 11,384 shares in the company, valued at $2,503,455.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Stephen D. Chubb sold 1,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $217.65, for a total transaction of $217,650.00. Over the last 90 days, insiders sold 6,195 shares of company stock worth $1,345,601. Company insiders own 1.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. SeaBridge Investment Advisors LLC purchased a new position in Charles River Laboratories Intl. during the 2nd quarter worth $35,000. Financial Management Professionals Inc. purchased a new stake in Charles River Laboratories Intl. in the second quarter worth $42,000. Private Advisor Group LLC bought a new position in Charles River Laboratories Intl. in the second quarter worth $45,000. Front Row Advisors LLC increased its holdings in shares of Charles River Laboratories Intl. by 22.1% during the second quarter. Front Row Advisors LLC now owns 260 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 47 shares in the last quarter. Finally, Legacy Wealth Planning LLC purchased a new stake in shares of Charles River Laboratories Intl. during the first quarter valued at $36,000.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Capital Gains

The Fly

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.